The supplied records describe separate Nasdaq-related events involving Evogene Ltd. and Tevogen Inc., rather than one underlying event. Evogene said Nasdaq granted an additional 180 calendar days, until March 29, 2027, to regain compliance with the $1 minimum closing bid-price requirement after 30 consecutive business days below that threshold. Tevogen said it regained compliance with Nasdaq's $50 million minimum market value of listed securities requirement and had already met the minimum market value of publicly held shares requirement, closing the related matters. Evogene's Nasdaq Capital Market listing and EVGN trading remain unaffected during the cure period, while Tevogen trades under TVGN on The Nasdaq Global Market.